What does a pharmaceutical company need to make the best decisions to deliver the greatest results?  In a word, they need intelligence – timely, accurate, global information, and the expertise to interpret it all.

Rich in pharmaceutical perspectives and created with insights from IMS experts worldwide, Intelligence.360 takes a look back and ahead at dynamics of the global pharmaceutical market and key events impacting the industry – with the depth and breadth of knowledge no one else can match.

Harbingers of Change

 Can companies put an end to the arms race for sales reps, as some have done for the first time in the US market? What does this mean for the future sales force model?
 Will the industry’s model of pure, ethically driven manufacturing companies sustain growth in the long run, as NCE launches signal a primary care meltdown?
 As home healthcare companies and specialty pharmacies emerge as distribution channels in Europe, are the current wholesalers on shaky ground?

These and other harbingers offer readers of Intelligence.360 critical perspectives on the 2005 events that are altering the global pharmaceutical landscape.

Managerial Implications

For most pharma companies, success over the next decade will be contingent on familiar, but pivotal issues surrounding excellence in commercial execution. Enabling commercial best practices is a management imperative and will determine which companies are the next generation of market leaders and which will be the also-rans.

For these and other through provoking perspectives, download your copy of IMS Intelligence.360 by clicking on the link below.

(This is the 2005 edition of Intelligence.360. The 2006 Edition is available immediately in hard copy format for IMS clients.  Please contact your IMS Account Team for more information.)
Intelligence.360 PDF